191 related articles for article (PubMed ID: 28472358)
21. A data-independent acquisition workflow for qualitative screening of new psychoactive substances in biological samples.
Kinyua J; Negreira N; Ibáñez M; Bijlsma L; Hernández F; Covaci A; van Nuijs AL
Anal Bioanal Chem; 2015 Nov; 407(29):8773-85. PubMed ID: 26396082
[TBL] [Abstract][Full Text] [Related]
22. Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users.
Krotulski AJ; Mohr ALA; Papsun DM; Logan BK
Drug Test Anal; 2018 Jan; 10(1):127-136. PubMed ID: 28608586
[TBL] [Abstract][Full Text] [Related]
23. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.
Michely JA; Helfer AG; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2015 Oct; 407(25):7831-42. PubMed ID: 26297461
[TBL] [Abstract][Full Text] [Related]
24. Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MS
Caspar AT; Brandt SD; Stoever AE; Meyer MR; Maurer HH
J Pharm Biomed Anal; 2017 Feb; 134():158-169. PubMed ID: 27915193
[TBL] [Abstract][Full Text] [Related]
25. Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry.
Caspar AT; Kollas AB; Maurer HH; Meyer MR
Talanta; 2018 Jan; 176():635-645. PubMed ID: 28917801
[TBL] [Abstract][Full Text] [Related]
26. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864).
Moosmann B; Bisel P; Westphal F; Wilde M; Kempf J; Angerer V; Auwärter V
Drug Test Anal; 2019 Mar; 11(3):541-549. PubMed ID: 30578721
[TBL] [Abstract][Full Text] [Related]
27. New psychoactive substances: Studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-α-PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine.
Richter LHJ; Maurer HH; Meyer MR
Toxicol Lett; 2017 Oct; 280():142-150. PubMed ID: 28782580
[TBL] [Abstract][Full Text] [Related]
28. Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry.
Habrdova V; Peters FT; Theobald DS; Maurer HH
J Mass Spectrom; 2005 Jun; 40(6):785-95. PubMed ID: 15827969
[TBL] [Abstract][Full Text] [Related]
29. In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples.
Noble C; Mardal M; Bjerre Holm N; Stybe Johansen S; Linnet K
Drug Test Anal; 2017 Aug; 9(8):1182-1191. PubMed ID: 27935260
[TBL] [Abstract][Full Text] [Related]
30. The detection of NBOMe designer drugs on blotter paper by high resolution time-of-flight mass spectrometry (TOFMS) with and without chromatography.
Botch-Jones S; Foss J; Barajas D; Kero F; Young C; Weisenseel J
Forensic Sci Int; 2016 Oct; 267():89-95. PubMed ID: 27572638
[TBL] [Abstract][Full Text] [Related]
31. Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine.
Caspar AT; Meyer MR; Westphal F; Weber AA; Maurer HH
Talanta; 2018 Oct; 188():111-123. PubMed ID: 30029353
[TBL] [Abstract][Full Text] [Related]
32. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS.
Vorce SP; Sklerov JH
J Anal Toxicol; 2004 Sep; 28(6):407-10. PubMed ID: 15516287
[TBL] [Abstract][Full Text] [Related]
33. 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): A Harmful Hallucinogen Review.
Kamińska K; Świt P; Malek K
J Anal Toxicol; 2021 Jan; 44(9):947-956. PubMed ID: 32128596
[TBL] [Abstract][Full Text] [Related]
34. Identification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples Associated with Clinical Intoxication.
Poklis JL; Dempsey SK; Liu K; Ritter JK; Wolf C; Zhang S; Poklis A
J Anal Toxicol; 2015 Oct; 39(8):607-16. PubMed ID: 26378134
[TBL] [Abstract][Full Text] [Related]
35. Identification of AKB-48 and 5F-AKB-48 Metabolites in Authentic Human Urine Samples Using Human Liver Microsomes and Time of Flight Mass Spectrometry.
Vikingsson S; Josefsson M; Gréen H
J Anal Toxicol; 2015; 39(6):426-35. PubMed ID: 25957385
[TBL] [Abstract][Full Text] [Related]
36. Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism.
Kintz P; Richeval C; Jamey C; Ameline A; Allorge D; Gaulier JM; Raul JS
Drug Test Anal; 2017 Jul; 9(7):1026-1033. PubMed ID: 27671107
[TBL] [Abstract][Full Text] [Related]
37. Rapid analysis of drugs of abuse and their metabolites in human urine using dilute and shoot liquid chromatography-tandem mass spectrometry.
Kong TY; Kim JH; Kim JY; In MK; Choi KH; Kim HS; Lee HS
Arch Pharm Res; 2017 Feb; 40(2):180-196. PubMed ID: 27988881
[TBL] [Abstract][Full Text] [Related]
38. In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry.
Mortelé O; Vervliet P; Gys C; Degreef M; Cuykx M; Maudens K; Covaci A; van Nuijs ALN; Lai FY
J Pharm Biomed Anal; 2018 May; 153():158-167. PubMed ID: 29494888
[TBL] [Abstract][Full Text] [Related]
39. In vitro metabolism studies on mephedrone and analysis of forensic cases.
Pedersen AJ; Reitzel LA; Johansen SS; Linnet K
Drug Test Anal; 2013 Jun; 5(6):430-8. PubMed ID: 22573603
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel psychoactive substances 25B-NBOMe and 4-CMC in biological material using HPLC-Q-TOF-MS and their quantification in blood using UPLC-MS/MS in case of severe intoxications.
Wiergowski M; Aszyk J; Kaliszan M; Wilczewska K; Anand JS; Kot-Wasik A; Jankowski Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1041-1042():1-10. PubMed ID: 27992785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
